Pharma Likelihood Of Approval
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.​
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you. ​
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities. ​
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence.
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From helping the C-suite refine strategy to powering innovation in marketing and R&D, our corporate use cases are endless. ​
- Investment firms: We help financial analysts develop robust long-term strategies and get alpha signals before the rest. ​
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions. ​
- Other sectors: From media to academia, we work with sectors as diverse as our data. ​
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on: ​
- Unique data: Proprietary datasets built from terabytes of data. Our unmatched intelligence gives you true strategic advantage.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.​
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge. ​
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them. ​
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.​
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform. ​
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Cemdomespib in Neuroinflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemdomespib in Neuroinflammation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cemdomespib in NeuroinflammationDrug Details:RTA-901 is under development for the treatment of diabetic peripheral neuropathic pain,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Tebotelimab in Hematological Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tebotelimab in Hematological Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Tebotelimab in Hematological TumorDrug Details:Tebotelimab (MGD-013) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy 1 To Target CD22 For B-Cell Acute Lymphoblastic Leukemia in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy 1 To Target CD22 For B-Cell Acute Lymphoblastic Leukemia in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Sabizabulin Hydrochloride in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sabizabulin Hydrochloride in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Sabizabulin Hydrochloride in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Drug Details:Sabizabulin...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - PXL-065 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PXL-065 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PXL-065 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:PXL-065 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Rucosopasem Manganese in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rucosopasem Manganese in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rucosopasem Manganese in Pancreatic Cancer Drug Details: GC-4711 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Sirolimus in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirolimus in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirolimus in Pulmonary Arterial Hypertension Drug Details: Sirolimus is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Sirolimus in Pulmonary Sarcoidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirolimus in Pulmonary Sarcoidosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirolimus in Pulmonary Sarcoidosis Drug Details: Sirolimus is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Rozibafusp Alfa in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rozibafusp Alfa in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rozibafusp Alfa in Systemic Lupus Erythematosus Drug Details: Rozibafusp...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Adrenocortical Carcinoma (Adrenal Cortex Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Adrenocortical Carcinoma (Adrenal Cortex Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.FPI-1434 in Adrenocortical Carcinoma (Adrenal Cortex Cancer)Drug Details:FP1-1434 is under...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.